Intellia Therapeutics (NTLA) said Sunday that 10 patients with hereditary angioedema patients in a phase 1/2 study were attack-free and treatment-free for a median of nearly two years after a single dose of its Crispr-based potential therapy lonvoguran ziclumeran.
The genetic disease recurrent swelling and possible abdominal pain.
With up to three years of follow-up, patients in the study experienced a mean reduction of monthly attacks of 98% after the single dose, the company said.
A phase 3, randomized, double-blind, placebo-controlled trial is ongoing, the company said.
Intellia also said it expects to submit a biologics license application in 2026 to support its plans for a US launch in 2027.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。